Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Interest expense	[1]	$ 13,971	$ 10,401	$ 12,663
Majority Shareholder | SG&A expense | Sunovion Pharmaceuticals Inc. Market Access Services Agreement
Expenses incurred under agreements		4,842	5,330
Majority Shareholder | MSG | Sunovion Pharmaceuticals Inc. Market Access Services Agreement
Expenses incurred under agreements			3,800
Majority Shareholder | MSG | SG&A expense | Sunovion Pharmaceuticals Inc. Market Access Services Agreement
Expenses incurred under agreements		4,800	3,700
Majority Shareholder | MSG | R&D expense | Sunovion Pharmaceuticals Inc. Market Access Services Agreement
Expenses incurred under agreements		0	58
Majority Shareholder | Sumitomo Dainippon Pharma Co., Ltd. | Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd.
Interest expense		$ 11,551	$ 9,766	$ 1,441

[1] Includes $11,551, $9,766, and $1,441 of interest expense under the Sumitomo Pharma Loan Agreement for the years ended March 31, 2022, 2021, and 2020, respectively